Based on recent studies, targeting and inhibiting the PI3K/AKT pathway can partially restore the sensitivity of melanoma cells to vemurafenib and trametinib, highlighting the significant role of this pathway in drug resistance (141, 144). The gene discussed is AKT1; the disease is melanoma.